X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
Angiomax-Generic (bivalirudin) is a direct thrombin inhibitor, which is now launched in the US market. It is indicated for treatment of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
Lead Product(s): Bivalirudin
Therapeutic Area: Hematology Product Name: Angiomax-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial. It is the only ready-to-use liquid format of bivalirudin on the market in the U.S.
Lead Product(s): Bivalirudin
Therapeutic Area: Hematology Product Name: Angiomax RTU
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Details:
The agreement aims to distribute Angiomax RTU (bivalirudin) injection, a direct thrombin inhibitor used to prevent blood clots in people with severe chest pain or other conditions who are undergoing a procedure called angioplasty, in the U.S.
Lead Product(s): Bivalirudin
Therapeutic Area: Hematology Product Name: Angiomax RTU
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: MAIA Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
